Corneal Cross-Linking for Keratoconus: Candidacy, Protocols and Where It Is Done

Understanding Keratoconus

Keratoconus is a progressive corneal disorder in which the normally round cornea thins and bulges outward into a cone shape. This distortion causes irregular astigmatism, blurred vision, light sensitivity, and difficulty with glasses correction. It typically presents in the teenage years and progresses through the twenties and thirties, stabilizing in most patients by age 40. Without treatment, severe cases may require a corneal transplant.

The key word is "progressive." Cross-linking is indicated when keratoconus is documented to be getting worse, not simply when it is diagnosed. Stable keratoconus in a 45-year-old does not need cross-linking. Progressive keratoconus in a 19-year-old needs it promptly.

How Cross-Linking Works

The procedure uses riboflavin (vitamin B2) drops to saturate the cornea, followed by controlled ultraviolet-A (UVA) light exposure. The combination creates new covalent bonds between collagen fibers in the corneal stroma, increasing corneal rigidity by up to 300%. The result is a stronger cornea that resists further thinning and distortion.

Two primary protocols exist. The standard "Dresden" protocol (epi-off) removes the corneal epithelium to allow riboflavin penetration, applies riboflavin drops for 30 minutes, then applies UVA light for 30 minutes. It has the strongest efficacy data. The transepithelial protocol (epi-on) uses chemical enhancers to drive riboflavin through the intact epithelium. It is less painful and has faster visual recovery but may be slightly less effective in halting progression. Accelerated protocols reduce the UV exposure time while increasing intensity, maintaining the same total energy dose.

Where Cross-Linking Is Available

CXL is FDA-approved in the US (Avedro/Glaukos KXL system, epi-off protocol). Many US ophthalmology practices now offer it, though availability varies by region. International markets (Europe, Latin America, Asia) have offered CXL for longer and often have more protocol options, including epi-on and accelerated variants. Cost varies significantly: $2,500 to $4,000 per eye in the US; $800 to $2,000 per eye in Colombia, Turkey, or India.

For patients with keratoconus who are considering cross-linking abroad, the same surgeon verification principles apply: check credentials, confirm experience with the specific protocol, and ensure the UV delivery system is a recognized medical device (Avedro, Peschke, UV-X). The riboflavin solution and UV parameters must match validated protocols, as deviations can result in under-treatment (progression continues) or over-treatment (corneal damage).

After Cross-Linking: What Comes Next

Cross-linking stabilizes the cornea but does not correct vision. Most patients still need contact lenses (scleral lenses are the gold standard for keratoconus) or glasses for visual correction. In some cases, intracorneal ring segments (ICRS, such as Intacs) can be implanted to flatten the cornea and improve contact lens fit. ICL implantation is an option for patients with stable keratoconus who want to reduce lens dependence, though it does not correct the irregular astigmatism. Corneal transplant remains the treatment of last resort for advanced disease that cannot be managed with lenses. The goal of cross-linking is to keep patients out of the transplant chair.

Diagnosing Progression

Cross-linking is indicated for progressive keratoconus, which means documented worsening over time. Progression is confirmed by serial corneal topography or tomography measurements (Pentacam, Orbscan) showing increasing maximum keratometry (Kmax), thinning at the thinnest point, or changes in the posterior corneal surface. Guidelines generally define progression as an increase of 1 diopter or more in Kmax over 6 to 12 months, or a decrease of 5% or more in thinnest pachymetry. A single measurement showing a steep cornea is not sufficient; you need at least two measurements separated by months to confirm the trend.

This is important because some patients are diagnosed with keratoconus on a single visit and immediately told they need cross-linking. Without documentation of progression, the procedure may be premature. A teenager with early keratoconus detected on screening is at high risk of progression and may warrant preemptive treatment, but this should be discussed explicitly as a risk-based decision rather than presented as routine.

Combined Procedures: CXL Plus

Cross-linking is sometimes combined with other procedures for enhanced outcomes. CXL combined with intracorneal ring segments (ICRS) first implants the rings to flatten the cornea, then cross-links to lock in the improved shape. This combination can improve both visual function and structural stability. CXL combined with PRK (photorefractive keratectomy) simultaneously strengthens the cornea and corrects some of the refractive error. This "Athens protocol" has been practiced for over a decade in Europe and has promising long-term data, but is considered off-label in the US.

These combined procedures are more available outside the US, where regulatory frameworks are more flexible for off-label combinations. Patients traveling abroad for cross-linking may have access to combined protocols that are not routinely offered at US practices. Discuss the risks and benefits of combined versus sequential treatment with your ophthalmologist.

Cost Comparison Across Markets

Many US insurance plans now cover cross-linking since its FDA approval. However, coverage often requires documentation of progression, prior authorization, and may be limited to the epi-off protocol. Patients with high-deductible plans or without ophthalmology coverage may find that treatment abroad is more cost-effective, especially when combined with other procedures.

Life After Cross-Linking

Cross-linking stabilizes the disease but does not turn back the clock. Patients with moderate keratoconus still have irregular corneas after the procedure and still need visual correction. The most common post-CXL visual correction is scleral contact lenses, rigid gas permeable (RGP) lenses that vault over the entire corneal surface and create a smooth optical surface with a tear reservoir underneath. Scleral lenses provide sharper vision than glasses or soft contacts for irregular corneas and are tolerated well by most keratoconus patients.

For patients who want to reduce lens dependence after stabilization, intracorneal ring segments (ICRS, such as Intacs or Keraring) can be implanted to flatten the cone and reduce irregular astigmatism. Some patients achieve functional vision with glasses after ICRS implantation, though most still benefit from contact lenses for optimal acuity. Topography-guided PRK combined with cross-linking (the Athens protocol) is another option for simultaneous stabilization and partial correction, available at select international centers.

Monitoring After Cross-Linking

After CXL, regular monitoring with corneal topography is essential. The first post-procedure topography is typically done at 3 months (earlier scans may show temporary changes from the healing process). Subsequent scans at 6, 12, and 24 months confirm that the cornea has stabilized. Stable Kmax readings over 12 to 24 months indicate successful cross-linking. Any increase in Kmax beyond the measurement variability of the device (±0.5 diopters) warrants investigation and potentially a repeat cross-linking procedure, which is needed in under 5% of patients when epi-off CXL is used initially.

Patients should maintain their monitoring schedule even when vision feels stable. Keratoconus progression is not always symptomatic, and topographic changes can precede noticeable vision loss by months. This is especially important for young patients (under 25) whose disease has the highest progression risk.